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Abstract
Background: There is concern amongst clinicians that the fixed dosing strategy of ri-
varoxaban for the treatment of venous thromboembolism (VTE) might not be optimal 
in those patients under or overweight.
Objective: To develop a pharmacokinetic model for rivaroxaban, based on real- world 
patients, specifically focusing on the impact of patients’ body weight on rivaroxaban 
pharmacokinetics.
Patients/methods: One hundred and one patients prescribed rivaroxaban prophylac-
tic or treatment doses for the prevention or treatment of VTE were recruited at a 
London teaching hospital. Subjects had up to 3 rivaroxaban concentrations measured 
during a single dosing period (trough, 1 and 3 hours post dose). Population pharma-
cokinetic analyses was conducted to develop a rivaroxaban model, which was subse-
quently evaluated.
Results: A one- compartment model with between- subject variability on rivaroxaban 
clearance and volume of distribution, with a combined (additive and proportional) 
error model, best fitted the data. Following a full covariate analysis, creatinine clear-
ance on rivaroxaban clearance was found to be the significant covariate impacting on 
the pharmacokinetic profile of rivaroxaban in the dataset.
Conclusions: Our results suggest that the most important covariate impacting on ri-
varoxaban pharmacokinetics is creatinine clearance and the weight alone has little 
effect. These findings are in line with previous studies for rivaroxaban. Larger datasets, 
from real- world patients who are followed longitudinally, should be conducted to pro-
vide front- line clinicians with further reassurance when prescribing rivaroxaban for 
the acute management of VTE.
K E Y W O R D S
anticoagulation, obesity, pharmacokinetics, rivaroxaban, weight
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1  | INTRODUCTION
The direct Xa- inhibitors are attractive anticoagulants relative to tradi-
tional anticoagulants.1 Post- regulatory studies, along with real- world 
studies, suggest that these direct oral anticoagulants (DOACs) are safe 
and effective,2–4 however, since their availability in clinical practice 
there has been some debate about whether the one- size- fits- all ap-
proach with these agents is the best way to use them.5,6 A particular 
cohort of patients where uncertainty exists with this dosing strategy 
are those patients at the extremes of weight. In their summary of 
product characteristics, the manufacturers of rivaroxaban state that 
in patients who are at the extremes of weight (<50 kg or >120 kg), 
only a small influence of weight on patients’ rivaroxaban plasma con-
centrations (<25%) is observed and no dose adjustment is necessary.7 
This conclusion is derived from a small pharmacokinetic study in 36 
healthy volunteers, administered 10 mg of rivaroxaban8; how well the 
results from such a study translate to clinical outcomes is difficult to 
determine. The lack of robust data has left clinicians wondering if the 
fixed dosing strategy truly is sufficient for those in obese category 
class II or III and perhaps too much for patients <50 kg.
With the prevalence of obesity increasing substantially in recent 
years, obese patients are no longer exceptional in clinical practice. 
This issue is particularly relevant in the acute management of venous 
thromboembolism (VTE), where it’s important to efficiently manage 
the thrombosis and prevent further morbidity and mortality. Equally, 
more frail patients, and/or underweight patients are presenting to 
clinic with acute VTE and one questions the wisdom in prescribing 
the same dose that would be given to patients of no frailty, often 
larger individuals. The DOACs dosing strategy is very different to that 
employed by low molecular weight heparin (LMWH), where dosing 
is based on a mg/kg or IU/kg basis, despite the LMWHs having pre-
dictable pharmacokinetic profiles.9 Weight is also a well- recognized 
covariant, impacting on the response to warfarin therapy.10
Whilst pharmacokinetic studies and pharmacokinetic models already 
exist for rivaroxaban,11–14 they do not currently provide sufficient evi-
dence for clinicians prescribing for patients at the extremes of weight, 
in determining whether the doses are safe and effective. In recent years, 
both a sub- analysis of the Einstein Deep Vein Thrombosis/Pulmonary 
Embolism (DVT/PE) studies15 and a UK study16 have begun to assess the 
effect of extremes of body weight and clinical outcomes with standard- 
dose rivaroxaban in the treatment of VTE, with both reporting that the 
fixed- dose rivaroxaban strategy did not impact on clinical outcomes in 
those at the extremes of weight through different methods employed 
in these individual studies. Current Scientific and Standardisation 
Committee (SSC) guidance of the International Society of Thrombosis 
and Haemostasis (ISTH) on the use of DOACs in obese patients makes 
three recommendations17: (i) to use appropriate standard dosing of 
DOACs in patients up to 40 kg/m2 and weight 120 kg for VTE prevention 
and treatment and prevention of ischemic stroke and systemic arterial 
embolism in NVAF, (ii) not to use DOACs in patients with a BMI >40 kg/
m2 or weight >120 kg due to limited data and available Pharmacokinetic/
Pharmacodynamic (PK/PD) evidence suggesting decreased drug expo-
sure, peak concentration, and shorter elimination half- lives with increas-
ing weight, and (iii) if DOACs are used in patients with a BMI >40 kg/m2 
or weight >120 kg, then to check drug- specific peak and trough level. 
If the drug level is reported back within the expected range, continua-
tion of the DOAC seems reasonable. The guideline authors suggest if the 
drug level is found to be below the expected range, then the guidance 
committee suggest changing to a Vitamin K Antagonist (VKA) rather than 
adjusting the dose of the DOAC. No guidance is provided by the SSC on 
what to do in patients with a weight <50 kg. The ISTH guidance is inter-
esting, as it implies that all DOACs have a similar pharmacokinetic profile. 
Whilst it’s acknowledged that all of the DOACs have a more predictable 
pharmacokinetic profile relative to VKAs, each DOAC has its own distinct 
pharmacokinetic profile worthy of individual consideration when consid-
ering patients at the extremes of weight.
Clinicians need more robust data before they can be sure of the 
optimal dosing strategy of each individual DOAC in this particular co-
hort of patients. In our hospital, rivaroxaban is the first line agent for 
the management of VTE and we wanted to begin to better understand 
the relationship between body weight and rivaroxaban exposure, par-
ticularly for the management of acute VTE.
2  | OBJECTIVES
To develop a pharmacokinetic model for rivaroxaban, based on real- 
world patients, specifically focusing on the impact of patients’ body 
weight on rivaroxaban pharmacokinetics.
3  | METHODS
3.1 | Study setting and recruitment
This study saw collaboration between the departments of haematol-
ogy and orthopaedic surgery at King’s College Hospital (KCH). KCH is 
Essentials
• The optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known.
• A pharmacokinetic study was conducted based in real-world patients in a London teaching hospital.
• In the cohort of patients studied, weight on its own did not impact significantly on rivaroxaban pharmacokinetics.
•  A larger study with patients in the weight categories of interest from the real-world population is required to further clarify the 
situation.
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a 1000- bedded London teaching hospital based in South East London, 
providing tertiary care for cardiology, neurology, haematology, and liver 
specialities. The orthopaedic surgery department at KCH conducts ~10 
elective knee or hip replacements per week. Following surgery, patients 
are routinely prescribed VTE thromboprophylaxis with enoxaparin (a 
LMWH), administered by subcutaneous injection for the duration of 
their inpatient stay and then rivaroxaban 10 mg daily following dis-
charge from hospital. Rivaroxaban is continued for 2 weeks for elective 
knee replacement patients and 4 weeks for elective hip replacements.
The thrombosis service at KCH provides acute and chronic man-
agement of all patients who have suffered an acute DVT/PE and for 
patients managed with long- term anticoagulation for the prevention 
of recurrent VTE. At the time of the study (2013), first- line treatment 
with LMWH and warfarin was gradually phased out and replaced with 
rivaroxaban at a dose of 15 mg twice daily for 3 weeks, followed by 
20 mg daily thereafter, following rivaroxaban’s license and NICE ap-
proval in the UK in the summer of 2012.18
Patients were eligible for the study if they were 18 years of age or 
older and were prescribed rivaroxaban for the aforementioned indi-
cations in these departments. Patients were excluded from the study 
if they had a documented allergy to rivaroxaban, if they had signifi-
cant renal function impairment (CrCl <30 mL/min–using the Cockcroft 
Gault method of calculation19), if they were prescribed the following 
concomitant drugs which are known to significantly impact on rivar-
oxaban concentrations: clarithromycin, telithromycin, HIV protease 
inhibitors, ketaconazole, itraconazole, voriconazole, and posaconazole, 
or if they had significant liver disease or deranged baseline coagulation.
For the orthopaedic population, eligible patients were identified 
soon after their procedure on the orthopaedic ward. For the VTE pop-
ulation, eligible patients were identified following a positive diagnosis 
through either the outpatient DVT service or thrombosis clinic in the 
haematology department.
All patients provided informed written consent prior to partici-
pation. At the time of consent, all participants were given a book to 
record the exact times they took their rivaroxaban tablets each day 
until they were seen by SB for the index study visit for blood sampling. 
Where doses were missed (if any), patients were asked to record these 
in the book provided by SB.
3.2 | Blood sampling
Subjects were asked to take their rivaroxaban tablets at a specific 
time of day in relation to their follow- up visit to the hospital as part 
of routine clinical care. On the day of their follow- up visit to the 
hospital (index study visit), patients had up to three blood samples 
drawn (at different times), to assess how the concentration of rivar-
oxaban was changing with time. The number of samples the patients 
had drawn was dictated by the patients themselves (minimum of 1 
and maximum of 3). On the day of their visit, patients arrived to the 
hospital not having taken their rivaroxaban. SB then took a blood 
sample (trough) and asked the patient to take their rivaroxaban. One 
hour later, a further sample was taken and a third sample was taken 
3- 4 hours post dose.
3.3 | Sampling handling and analysis
Anti- Xa activity was used to characterize the rivaroxaban concentra-
tion. For determination of anti- Xa activity, 2.7 mL blood (9 vol) sample 
was collected in 0.109 M (3.2% trisodium citrate) Becton- Dickinson 
Vacutainer. Following collection, the sample was centrifuged in a Rotina 
420 R centrifuge (Hettich Zentrifugen) and double spun for 7 minutes 
at 2500 g and frozen within 1 hour of sample collection. The samples 
were stored at −40°C until analyzed. Samples were thawed and ana-
lyzed in weekly batches using the STA anti- Xa assay (Diagnostica Stago, 
Asnieres-sur-Seine, France), with appropriate rivaroxaban calibrators 
and controls, on the STA- R evolution analyzer (Diagnostica Stago) in the 
laboratory at King’s College Hospital. Results were reported as ng/mL. 
The lower and upper limits of quantification for this assay are <20 ng/mL 
and >500 ng/mL, respectively. This functional assay has been shown to 
correlate well with analysis conducted using turbulent flow liquid chro-
matography with high- resolution mass spectrometry.20
3.4 | Analysis and PK modelling
Pharmacokinetic (PK) analysis was conducted using the method of non- 
linear mixed effects modelling. Population PK modelling fits mathematical 
models to describe pharmacokinetic data that arises from more than one 
individual.21 The method does not require each subject to provide suffi-
cient data to characterize their own PK profile, as PK information is shared 
between individuals to develop the population PK profile.21 The method 
therefore allows the use of sparse sampling study designs, having an ob-
vious advantage when applied in the clinic setting. A typical population 
PK model integrates both a covariate and a statistical model.22,23 The co-
variate model describes relationships between PK parameters and patient 
characteristics. The statistical model describes the variance in PK between 
and within individuals as well as residual variance due to biological vari-
ability, measurement errors, and errors in the fit of the model to the data.
3.5 | Developing the rivaroxaban model
Initially, several structural base models were developed, eg, a one- 
and two- compartment model and the model which best fit the data 
was selected. Goodness- of- fit plots, a statistical improvement in the 
fit of the model to the data using the objective function (minus twice 
the log- likelihood of the data), assessment of the precision of the pa-
rameter estimates, and residual variability were the criterion used to 
evaluate and choose the base model to take forward for full covariate 
analysis. The specific covariates evaluated as part of this analysis were 
those which had a mechanistic meaning: age, weight, BMI, lean body- 
weight, creatinine, creatinine clearance, ethnicity, and gender. The 
covariate analysis involved a classical graphical approach, plotting in-
dividual estimates of the pharmacokinetic parameters random effects 
(ETAs) against each of the covariates being considered for inclusion in 
the model. Each selected covariate was then tested by univariate addi-
tion into the base model to confirm its relevance. A decrease in objec-
tive function value of at least 6.64 (P < .01), was required to retain the 
covariate in the intermediate model. All significant covariates were 
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then simultaneously added to the base model and their continued rel-
evance was evaluated using a stepwise backward elimination method, 
where each covariate was removed singularly from the model. An in-
crease in the objective function value of greater than 10.82 (P < .001) 
was required to retain the covariate in the final model.
Both the base and the final models were evaluated using a non- 
parametric bootstrap procedure (1000 replicates).24 The final model 
was additionally evaluated using a visual predictive check,25 where the 
5th, 50th, and 95th prediction intervals, simulated from the posterior 
distribution of the final model parameter estimates were overlaid with 
the 5th, 50th, and 95th percentiles from the observed data. A well- 
performing model would see the observed percentiles and simulated 
prediction intervals superimposed.
Pharmacokinetic analysis was conducted using NONMEM (ICON 
plc, Dublin, Ireland) version 7.2.1326 and graphical analysis associated 
with the PK modelling and simulation was conducted using “R” version 
2.14.1.40.
3.6 | Ethical approval
The study was approved by the London Harrow Ethics Committee; 
REC reference number: 12/LO/1951 and the local Research and 
Development Committee at King’s College Hospital.
4  | RESULTS
During the recruitment period (June 1, 2013- April 30, 2014), 101 pa-
tients consented to take part in the study. Demographic information 
on these patients is presented in Table 1. Ninty- seven patients were 
either being managed for acute VTE or the secondary prevention of 
VTE and 4 patients were prescribed prophylactic rivaroxaban in the 
context of elective orthopaedic surgery prophylaxis. The 101 subjects 
provided 193 samples for PK modelling purposes, 24 patients (24%) 
providing 3 samples at the index study visit, 45 patients providing 2 
samples (44%), and 32 subjects (32%) providing 1 sample.
Figure 1 illustrates the breadth of samples generated in this study, in 
relation to body weight, and Figure 2 illustrates the breadth of concen-
trations in relation to time after dose of the samples generated by this 
study. Of these, 14 samples were below or above the level of quantifi-
cation (BLQ or ALQ) of the assay being utilized. ALQ or BLQ were han-
dled using a mixed- method approach. For BLQ <20 ng/mL, where results 
were obtained from the analyzer, these were entered into the model as 
reported, otherwise half BLQ (0.10 ng/mL) were entered into the dataset. 
ALQ values (>500 ng/mL) were entered into the dataset, as 500 ng/mL. 
The total BLQ or ABL for the dataset comprised <10% of the total data-
set, and research suggests that when this is the case, that no one single 
approach is superior for handling BLQ/ABL for PK modelling purposes.27
4.1 | Rivaroxaban base model development
Several base models were initially explored (ie, one- and 
two- compartment models). A one- compartment model with 
between- subject variability on rivaroxaban clearance and vol-
ume of distribution with a combined (additive and proportional) 
error model best fitted the data (Table 2, with associated 1000 
bootstrap).
A full covariate analysis was then conducted evaluating the fol-
lowing selected covariates: weight, lean body weight, creatinine, 
creatinine clearance, ethnicity, gender, and BMI (see Table 3). Only 
TABLE  1 Demographic information on the patients recruited
Patient demographics (n = 101)
Age, years (mean range) 52 (20- 86)
Male/female (%) 58/42
Body weight, kg (mean ± SD) 88.0 (23.4)
<50 kg (%) 2
50- 100 kg (%) 81
>100 kg (%) 17
Lean body weight, kg (mean ± SD) 57.0 (11.3)
BMI, kg/m2 (%)
16- 18.49 1
18.5- 24.9 27
25- 29.9 32
30- 34.9 21
35- 39.9 14
≥40 6
Creatinine clearance, (%)
>80 mL/min 67
50- 79 mL/min 25
30- 49 mL/min 7.8
<30 mL/min 0.2
Indication for anticoagulation (%)
Acute VTE first event 58
Acute recurrent event 26
Secondary prevention of VTE 12
Elective orthopaedic VTE prophylaxis 4
Dose of rivaroxaban (%)
20 mg once a day 38
15 mg twice a day 57
10 mg once a day 4
15 mg once a day 1
Proportion of samples provided at each time point (%)
Trough only 32
Trough and 1 hour post dose 44
Trough, 1 and 3 hours post dose 24
Ethnicity (%)
White 74
Afro- Caribbean 21
Other 5
BMI, body mass index; SD, standard deviation; VTE, venous 
thromboembolism.
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creatinine clearance on clearance met the criteria for inclusion to the 
final model.
The final rivaroxaban PK estimates for typical values of CL and Vd 
thus can be represented mathematically as: 
 
Table 4 provides the estimates for the PK parameters for the final 
model developed.
Finally, a visual predictive check was conducted (Figure 3), demon-
strating a well- performing rivraoxaban PK model.
CL=POPCL×(CrCl∕79)0.434
Vd=POPV
F IGURE  1 Breadth of rivaroxaban samples obtained with respect 
to bodyweight, in relation to time after dose
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F IGURE  2 Breadth of rivaroxaban concentrations obtained with 
respect to time after dose
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TABLE  2 Base model PK estimates with associated bootstrap 
(1000 replicates)
Parameter
Base model 
estimates (%SE)
1000 Bootstrap median 
(2.5th- 97.5th)
CL (L/h) 8.59 (7) 8.35 (7.34- 9.55)
Vd (L) 104 (13) 99.10 (79.2- 130.4)
Ka (/h) 1.32 (24) 1.28 (0.78- 2.28)
ωCL (%CV) 56 (25) 73.8 (61.6- 81.8)
ωVd (%CV) 66 (52) 82.6 (56.6- 94.3)
Proportional error 
(%)
28.6 (84) 51.3 (5.6- 65.6)
Additive error 
(ng/mL)
0.018 (38) 0.018 (0.008- 0.027)
Objective 
function
−853.710 – 
CL, clearance; Ka, absorption rate constant; SE, standard error; Vd, vol-
ume of distribution; ωCL, between subject variability on rivaroxaban 
clearance; ωVd, between subject variability on rivaroxaban volume of 
distribution.
TABLE  3 Univariate covariate addition to the base model
Model Covariate ∆OBV
4 CL × (CrCl/79)0.434 −14.65
5 CL × (Wt/87)0.0403 −0.05
6 CL × (Age/51)−0.335 −6.91
7 CL × (Cre/81)−0.44 −5.46
8 CL × (LBW/58)0.275 −1.45
9 CL × (BMI/30)−0.126 −0.55
10 CL × (ETHN)−0.038 −0.09
11 Vd × (ETHN)
0.139 −0.64
12 Vd × (BMI/30)
−0.027 −0.01
13 Vd × (LBW/58)
0.264 −0.69
15 Vd × (Cre/81)
0.454 −0.30
16 Vd × (Age/51)
0.0539 −0.07
17 Vd × (Wt/87)
0.0657 −0.07
18 Vd × (CrCl/79)
−0.137 −0.65
∆OBV represents the change in the base model objective function with the 
addition of the covariate. The base line OBV was −853.710. All models 
minimised successfully. Gender was modelled as a “what- if” statement and 
was not found to impact significantly on CL or Vd (∆OBV 0.07 for CL and 
∆OBV 0.09 for Vd).
BMI, body mass index; CL, clearance; CrCl, creatinine clearance; Cre, 
serum creatinine; ETHN, ethnicity; LBW, lean body weight; Vd, volume of 
distribution; Wt, actual body weight.
     |  185BARSAM et Al.
5  | DISCUSSION
This study aimed to develop a PK model for rivaroxaban derived from 
real- world patients, with a particular focus on body weight. From the 
dataset generated, a relatively well- performing PK model for rivaroxa-
ban was developed (Table 5 in comparison to PK models published 
by the manufacturers of rivaroxaban) and the data suggests that the 
single best co- variant predicting rivaroxaban exposure is creatinine 
clearance.
Elimination of rivaroxaban is via a dual pathway: renal excretion 
and metabolic degradation. Approximately 1/3 of rivaroxaban is elim-
inated as unchanged active drug in the urine, with active renal secre-
tion accounting for 30% and glomerular filtration for 6%. The specific 
transporters involved with active renal secretion of rivaroxaban are 
 P- glycoprotein (P- gp) and breast cancer resistance protein (BCRP). The 
remaining two- thirds of rivaroxaban is metabolized by several cyto-
chrome P450 enzymes (CYP 3A4/5, CYP2J2) and CYP- independent 
mechanisms.28 Given this, and the fact that active renal secretion pre-
dominates renal clearance, perhaps it’s not surprising that renal function 
is the significant predictor of rivaroxaban exposure. It’s also important 
to remember that this clearance mechanism is unique to rivaroxaban 
and what is reported here, may not be the case for the other currently 
available DOACs. We were surprised that weight did not feature more 
significantly as a covariant in our study. There are three possible rea-
sons for this: (i) weight is not an important determinant of rivaroxaban 
pharmacokinetics and the current manufacturers recommendations are 
correct, (ii) we did not have enough patients represented in the weight 
categories of interest in our study to pick this out correctly, or (iii) the 
CrCl equation utilized in this study and commonly used in clinical prac-
tice, already has weight accounted for, as follows: 
where weight in the present study was computed using a LBW equa-
tion,29 and F = 1.04 for females and 1.23 for males.
Research suggests that both renal and liver activity increases in the 
obese,30 therefore one might predict that clearance also increases in this 
population. Han and colleagues31 stipulate that (i) obese patients exhibit 
a higher absolute drug clearance compared to their normally weighted 
counterparts, (ii) clearance of drugs does not increase linearly with total 
body weight, however (iii) clearance and lean body weight (as calculated 
through a mechanistically derived lean body weight equation) are linearly 
correlated. Perhaps with more patients in the specific weight categories 
of interest, weight would come through as important covariant on rivarox-
aban pharmacokinetics and further data is clearly required to clarify this.
On closer examination of the model developed here, the estimates 
for Vd are greater than that described in the PK models previously pub-
lished by the manufacturers of rivaroxaban. This illustrates how the typ-
ical pharmacokinetic estimates will vary in the real- world population in 
comparison to those volunteers who took part in the earlier studies and 
confirms the need for further PK studies similar to the present study, 
with larger datasets in the future, from real- world patients.
Some data from other studies is becoming to emerge. Di Nisio 
and colleagues15 completed a sub- analysis of the EINSTEIN DVT/PE 
studies, with the aim of determining the incidence of major bleeding 
in patients with low body weight and recurrent VTE in patients with 
high body weight. Using a Cox proportional hazards model, no asso-
ciation was found between bodyweight and BMI and risk of recurrent 
VTE, major bleeding or clinically relevant bleeding. The authors of this 
sub- analysis conclude that body weight is not associated with an in-
creased risk of major bleeding or recurrent VTE in patients with either 
a low or high bodyweight. However, the data from this study is derived 
CrCl=
F×(140−age)×weight
Scr
F IGURE  3 Visual predictive check from final model. Red lines 
represent the observed anti- Xa activities and the blue lines represent 
the simulated anti- Xa activities. Fifth (dashed), median, and 95th 
(dashed) percentiles are presented for both sets of concentrations
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TABLE  4 The typical value of clearance and volume of 
distribution from the final model developed with the associated 
bootstrap results
Parameter
Final covariate 
model (%SE)
1000 Bootstrap median 
(2.5th- 97.5th)
CL (L/h) 8.86 (7) 8.57 (7.58- 9.79)
Vd (L) 101 (12) 95 (75.3- 125)
Ka (/h) 1.21 (34) 1.21 (0.72- 2.13)
FACCrCl 0.434 (30) 0.416 (0.215- 0.619)
ωCL (%CV) 48 (99) 64.5 (53.8- 78.2)
ωVd (%CV) 60 (247) 82.1 (38.7- 96.1)
Proportional error 
(%)
31 (215) 52.7 (5.62- 67.2)
Additive error (ng/
mL)
0.016 (112) 0.016 (0.006- 0.025)
Objective function −868.355 – 
CL, clearance; FACCrCL is the exponent on creatinine clearance as a covari-
ate on clearance; Ka, absorption rate constant; SE, standard error; Vd, vol-
ume of distribution; ωCL, between subject variability on rivaroxaban 
clearance; ωVd, between subject variability on rivaroxaban volume of 
distribution.
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from the clinical trials of rivaroxaban, and its questionable how well 
represented the extremes of weight were in these studies. Archillage 
and colleagues16 assessed 167 acute VTE patients, stratified into three 
groups based on weight (<50 kg, 50- 120 kg, >120 kg), with patients 
having rivaroxaban concentration measured 2- 4 hours post dose (peak). 
Patients were followed for a median of 14 months. The authors report 
that peak rivaroxaban plasma concentrations were significantly higher 
in patients with a lower body weight (<50 kg). Those patients with a 
weight >120 kg had comparable rivaroxaban peak concentrations to 
those of standard body weight. The authors also report that weight did 
not appear to impact on clinical outcomes. Although the results from 
this small study are encouraging, it’s important to note that peak sam-
pling is not considered the best time- point, when evaluating the clear-
ance of a drug, which would be the case when wanting to evaluate the 
impact of weight. Trough sampling would have been more informative. 
More recently a study in the setting of bariatric surgery, where prophy-
lactic doses of rivaroxaban were given pre- and post- bariatric surgery, 
found single doses of rivaroxaban resulted in similar systematic drug 
exposures prior to and after bariatric surgery.32 The median weights of 
patients in this study having sleeve gastrectomy was 137 kg (range 112- 
153) and 101.5 kg (range 96- 120) for Roux- en- Y gastric bypass, ie, not 
excessively obese.
The findings from these afore- mentioned studies are reassuring, 
and in our study, we also found patients’ rivaroxaban concentrations 
to be comparable when comparing the standard body weight patients 
and those in the obese category.
Our findings suggest that rivaroxaban certainly behaves differently 
from other traditional anticoagulants, in the extremes of weight pop-
ulation, ie, that the dose of anticoagulant does not need to increase in 
line with weight. The findings we report here are specific to rivarox-
aban. Whilst the general principal of what we found might translate to 
other DOACs, due to their unique pharmacokinetic profiles, specific 
studies with each DOAC should be conducted to assess if the same is 
true for each one.
The results of our study, should be considered in the context 
of their limitations. We conducted this study, at a time when ex-
perience with rivaroxaban was emerging and the agent had newly 
become available; the number of patients prescribed the drug in 
the extremes of weight category was less at the time of recruitment 
compared to our current practice now and that described in ISTH 
guidance.17 Therefore, the number of patients in the extremes of 
weight categories in the present study, could have been greater. 
Despite this, a well performing rivaroxaban model was developed 
and with further pharmacokinetic data coupled with outcome data, 
further direction to offer clinicians should be possible.
6  | CONCLUSION
Our study developed a pharmacokinetic model rivaroxaban model fo-
cusing on the impact body weight had on rivaroxaban exposure across 
a wide weight range, derived from a real- world population. Our study 
suggests that weight on its own is not a good predictor of rivaroxaban 
exposure, and found renal function computed by the Cockcroft–Gault 
equation to be a significant covariant explaining rivaroxaban exposure. 
Further studies with larger data- sets from the extremes of weight co-
hort of patients will confirm/refute the findings from our work.
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TABLE  5 Comparison of previous PK models of rivaroxaban and the model developed in this study
PK parameter Mueck et al.11 Mueck et al.12 Mueck et al.13 Xu et al.14 Present study
Compartment model One One One One One
CL (L/h), (%SE) 7.51 (4.1) 7.3 (4) 5.67 (3.70) 6.48 (2.21) 8.86 (7)
Vd (L), (%SE) 58.2 (4.9) 49.1 (4.3) 54.4 (3.80) 57.9 (1.16) 101 (12)
Ka (/h), (%SE) 1.49 (10.0) 1.81 (8.3) 1.23 (5.0) 1.24 (3.28) 1.21 (34)
ωCL (%CV) 38.2 (10.0) 38.6 (8.3) 39.9 (7.60) 31.3 (4.72) 48 (99)
ωVd (%CV) 32.4 (23.0) – 28.8 (11.4) 10.0 (3.66) 60 (247)
ωKa (%CV) – – – 139 (0.30) – 
Proportional residual error (%) 
(%SE)
52.6 (3.0) 37.1 (4.0) 40.7 (3.20) – 31.0 (215)
Additive error (ng/mL) (%SE) – – – 0.352 (1.09) 0.016 (112)
CL, clearance; Ka, absorption rate constant; SE, standard error; Vd, volume of distribution; ωCL, between subject variability on rivaroxaban clearance; ωVd, 
between subject variability on rivaroxaban volume of distribution.
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